|
Daily Medical Update
Peripheral arterial disease
Saturday, August 29, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Current medical research and opinion (2026) - Meta-Analysis
Key Findings
- PCSK9 inhibitors reduced major adverse cardiac events (HR 0.77, 95% CI 0.65-0.92) across 4,563 patients.
- LDL-C fell by a mean 55.76 mg/dL (95% CI -63.19 to -48.34).
- Major amputation, mortality, and walking performance showed favorable but non-significant trends.
📋 Practice Implication: For PAD patients whose LDL-C remains above goal on maximally tolerated statin therapy, PCSK9 inhibition is a reasonable adjunct for cardiovascular risk reduction, while limb and functional benefits remain unproven.
|
Diabetes research and clinical practice (2026) - Meta-Analysis
Key Findings
- GLP-1-based therapies were associated with fewer major adverse limb events (HR 0.59, 95% CI 0.39-0.90).
- Major adverse cardiovascular events were reduced (HR 0.67, 95% CI 0.53-0.85), with more consistent effects in diabetes.
- Stroke was reduced (HR 0.75, 95% CI 0.63-0.89), while myocardial infarction and mortality also declined with greater variability.
📋 Practice Implication: In diabetic patients with PAD, GLP-1-based therapy may offer limb and cardiovascular protection alongside metabolic treatment; substantial real-world heterogeneity supports individualized prescribing and follow-up.
|
Journal of the American Heart Association (2026) - Network Meta-Analysis
Key Findings
- Clopidogrel plus cilostazol had lower major adverse cardiac events than aspirin alone (HR 0.37, 95% CI 0.20-0.72).
- Clopidogrel monotherapy and aspirin plus low-dose rivaroxaban or ticagrelor also reduced major adverse cardiac events versus aspirin.
- Aspirin plus rivaroxaban or ticagrelor reduced major adverse limb events, but rivaroxaban-containing regimens and clopidogrel combinations increased major bleeding in the analysis.
📋 Practice Implication: Antithrombotic choice in PAD should be individualized: clopidogrel-based strategies may balance efficacy and safety, whereas dual-pathway or intensified regimens require explicit bleeding-risk assessment.
|
JACC. Cardiovascular interventions (2026) - Network Meta-Analysis
Key Findings
- Drug-coated balloons and drug-eluting stents improved primary patency versus PTA (OR 2.66 and 2.41, respectively).
- Drug-coated balloons and drug-eluting stents reduced binary restenosis versus PTA (OR 0.40 and 0.28, respectively).
- Drug-coated balloons reduced clinically driven target-lesion revascularization (OR 0.47), with no significant differences in amputation or mortality.
📋 Practice Implication: For symptomatic infrapopliteal disease, DCB or DES can improve vessel durability over plain angioplasty, but the absence of demonstrated amputation or mortality benefit keeps anatomy, wound status, and procedural risk central to device selection.
|
Acta diabetologica (2025) - Meta-Analysis
Key Findings
- Aspirin plus low-dose rivaroxaban was associated with fewer major adverse limb events than aspirin alone (OR 0.52, 95% CI 0.26-1.06).
- The composite of major adverse cardiovascular or limb events was lower with dual-pathway inhibition (OR 0.67, 95% CI 0.45-1.00).
- Net clinical benefit favored dual-pathway inhibition (OR 0.55, 95% CI 0.36-0.84), without a significant increase in major or fatal/critical-organ bleeding.
📋 Practice Implication: In symptomatic diabetic LE-PAD, aspirin plus low-dose rivaroxaban may reduce net cardiovascular and limb events, but the limited and indirectly estimated evidence calls for careful confirmation of bleeding risk before adoption.
|
|
💡
Summary
New evidence across five high-priority studies addresses lipid lowering, incretin therapy, antithrombotic selection, and infrapopliteal revascularization in peripheral arterial disease. The strongest signals were lower cardiovascular or limb event rates and better patency with selected therapies, while bleeding risk, real-world heterogeneity, and uncertain effects on amputation or mortality remain important qualifiers.
|
|